Skip to main content
Premium Trial:

Request an Annual Quote

Progenika to Develop Companion Dx for AMT Gene Therapy

NEW YORK (GenomeWeb News) – Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma plan to develop and market a diagnostic tool to rapidly diagnose patients who have lipoprotein lipase deficiency (LPLD) and may be candidates for an AMT therapeutic.

AMT said today that it will collaborate with Progenika to develop the LPLchip, which is based on Progenika's DNA-chip technology, to diagnose patients with complete and partial LPLD who may benefit from treatment with AMT's Glybera, a gene therapy.

AMT has released clinical data that it said show that Glybera can produce long-term health benefits for LPLD patients and can reduce acute pancreatitits, a complication of the disease. AMT plans to file the therapy for marketing in Europe by the end of this year.

"This collaborative project demonstrates how DNA-based diagnostics and highly targeted gene therapy can be combined to bring personalized medicine to patient groups whose medical needs were previously unmet," Progenika CEO Antonio Martinez said in a statement.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.